Ablation plus Transarterial Embolic Therapy for Hepatocellular Carcinoma Larger than 3 cm: Science, Evidence, and Future Directions

Andrew R. Lewis; Carlos A. Padula; J Mark McKinney; Beau B. Toskich

doi:10.1055/s-0039-1697641

Seminars in Interventional Radiology, Inhaltsverzeichnis

Semin intervent Radiol 2019; 36(04): 303-309
DOI: 10.1055/s-0039-1697641

Review Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Ablation plus Transarterial Embolic Therapy for Hepatocellular Carcinoma Larger than 3 cm: Science, Evidence, and Future Directions

Andrew R. Lewis

¹Division of Interventional Radiology, Department of Radiology, Mayo Clinic, Jacksonville, Florida

,

Carlos A. Padula

¹Division of Interventional Radiology, Department of Radiology, Mayo Clinic, Jacksonville, Florida

,

J Mark McKinney

¹Division of Interventional Radiology, Department of Radiology, Mayo Clinic, Jacksonville, Florida

,

Beau B. Toskich

¹Division of Interventional Radiology, Department of Radiology, Mayo Clinic, Jacksonville, Florida

› Institutsangaben

Abstract

Thermal ablation is widely regarded as definitive therapy for early-stage hepatocellular carcinoma, but its efficacy decreases in tumors greater than 3 cm. Extensive clinical studies have supported improved outcomes provided through combining transarterial embolic therapy with ablation in the treatment of larger tumors. This article will provide a survey of the science and data for combination therapy in both thermal and nonthermal ablation modalities, as well as describe emerging applications.

Keywords

hepatocellular carcinoma - radiofrequency ablation - microwave ablation - transarterial chemoembolization - transarterial embolization - cryoablation - thermal ablation - combination therapy - ablation - embolization

Volltext

Referenzen

References
1 Liu PH, Hsu CY, Hsia CY. , et al. Surgical resection versus radiofrequency ablation for single hepatocellular carcinoma ≤ 2 cm in a propensity score model. Ann Surg 2016; 263 (03) 538-545
2 Shiina S, Tateishi R, Arano T. , et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol 2012; 107 (04) 569-577 , quiz 578
3 Livraghi T, Giorgio A, Marin G. , et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 1995; 197 (01) 101-108
4 Chevallier P, Baudin G, Anty R. , et al. Treatment of hepatocellular carcinomas by thermal ablation and hepatic transarterial chemoembolization. Diagn Interv Imaging 2015; 96 (06) 637-646
5 Lee HJ, Kim JW, Hur YH. , et al. Conventional chemoembolization plus radiofrequency ablation versus surgical resection for single, medium-sized hepatocellular carcinoma: propensity-score matching analysis. J Vasc Interv Radiol 2019; 30 (03) 284-292.e1
6 Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer 2010; 116 (23) 5452-5460
7 Takayasu K, Arii S, Ikai I. , et al; Liver Cancer Study Group of Japan. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131 (02) 461-469
8 Sabel MS. Cryo-immunology: a review of the literature and proposed mechanisms for stimulatory versus suppressive immune responses. Cryobiology 2009; 58 (01) 1-11
9 Takaki H, Cornelis F, Kako Y, Kobayashi K, Kamikonya N, Yamakado K. Thermal ablation and immunomodulation: from preclinical experiments to clinical trials. Diagn Interv Imaging 2017; 98 (09) 651-659
10 Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 1999; 210 (03) 655-661
11 Livraghi T, Goldberg SN, Lazzaroni S. , et al. Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology 2000; 214 (03) 761-768
12 Chinn SB, Lee Jr FT, Kennedy GD. , et al. Effect of vascular occlusion on radiofrequency ablation of the liver: results in a porcine model. AJR Am J Roentgenol 2001; 176 (03) 789-795
13 Mostafa EM, Ganguli S, Faintuch S, Mertyna P, Goldberg SN. Optimal strategies for combining transcatheter arterial chemoembolization and radiofrequency ablation in rabbit VX2 hepatic tumors. J Vasc Interv Radiol 2008; 19 (12) 1740-1748
14 Rossi S, Garbagnati F, Lencioni R. , et al. Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology 2000; 217 (01) 119-126
15 Duan X, Zhou G, Han X. , et al. Radiofrequency ablation combined with transcatheter therapy in rabbit VX2 liver tumors: effects and histopathological characteristics. Acta Radiol 2015; 56 (01) 87-96
16 Brown KT, Do RK, Gonen M. , et al. Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. J Clin Oncol 2016; 34 (17) 2046-2053
17 Meyer T, Kirkwood A, Roughton M. , et al. A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. Br J Cancer 2013; 108 (06) 1252-1259
18 Facciorusso A, Bellanti F, Villani R. , et al. Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: a meta-analysis of randomized trials. United European Gastroenterol J 2017; 5 (04) 511-518
19 Lee IJ, Kim YI, Kim KW. , et al. Radiofrequency ablation combined with transcatheter arterial embolisation in rabbit liver: investigation of the ablation zone according to the time interval between the two therapies. Br J Radiol 2012; 85 (1019): e987-e994
20 Bhattacharya S, Novell JR, Winslet MC, Hobbs KEF. Iodized oil in the treatment of hepatocellular carcinoma. Br J Surg 1994; 81 (11) 1563-1571
21 Wissniowski TT, Hänsler J, Neureiter D. , et al. Activation of tumor-specific T lymphocytes by radio-frequency ablation of the VX2 hepatoma in rabbits. Cancer Res 2003; 63 (19) 6496-6500
22 Chen T, Guo J, Han C, Yang M, Cao X. Heat shock protein 70, released from heat-stressed tumor cells, initiates antitumor immunity by inducing tumor cell chemokine production and activating dendritic cells via TLR4 pathway. J Immunol 2009; 182 (03) 1449-1459
23 Duan XH, Li TF, Zhou GF. , et al. Transcatheter arterial embolization combined with radiofrequency ablation activates CD8(+) T-cell infiltration surrounding residual tumors in the rabbit VX2 liver tumors. OncoTargets Ther 2016; 9: 2835-2844
24 Peng ZW, Zhang YJ, Chen MS. , et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol 2013; 31 (04) 426-432
25 Chen QW, Ying HF, Gao S. , et al. Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2016; 40 (03) 309-314
26 Vogl TJ, Qian J, Tran A. , et al. Study on the effect of chemoembolization combined with microwave ablation for the treatment of hepatocellular carcinoma in rats. Diagn Interv Radiol 2017; 23 (02) 150-155
27 Puza CJ, Wang Q, Kim CY. Evaluation of the heat sink effect after transarterial embolization when performed in combination with thermal ablation of the liver in a rabbit model. Cardiovasc Intervent Radiol 2018; 41 (11) 1773-1778
28 Yi Y, Zhang Y, Wei Q. , et al. Radiofrequency ablation or microwave ablation combined with transcatheter arterial chemoembolization in treatment of hepatocellular carcinoma by comparing with radiofrequency ablation alone. Chin J Cancer Res 2014; 26 (01) 112-118
29 Thornton LM, Cabrera R, Kapp M, Lazarowicz M, Vogel JD, Toskich BB. Radiofrequency vs microwave ablation after neoadjuvant transarterial bland and drug-eluting microsphere chembolization for the treatment of hepatocellular carcinoma. Curr Probl Diagn Radiol 2017; 46 (06) 402-409
30 Vietti Violi N, Duran R, Guiu B. , et al. Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial. lancet. Gastroenterol Hepatol 2018; 3 (05) 317-325
31 Kollmar O, Richter S, Schilling MK, Menger MD, Pistorius GA. Advanced hepatic tissue destruction in ablative cryosurgery: potentials of intermittent freezing and selective vascular inflow occlusion. Cryobiology 2004; 48 (03) 263-272
32 Mala T, Frich L, Aurdal L. , et al. Hepatic vascular inflow occlusion enhances tissue destruction during cryoablation of porcine liver. J Surg Res 2003; 115 (02) 265-271
33 Guo Z, Ni H, Hu Yh, Xing Wg, Liu F. [Experimental study of hepatic bloodflow to the effect of cryoablation]. Beijing Da Xue Xue Bao 2008; 40 (02) 139-142
34 Zeng JY, Piao XH, Zou Z-Y. , et al. Cryoablation with drug-loaded bead embolization in the treatment of unresectable hepatocellular carcinoma: safety and efficacy analysis. Oncotarget 2018; 9 (07) 7557-7566
35 Xu KC, Niu LZ, Zhou Q. , et al. Sequential use of transarterial chemoembolization and percutaneous cryosurgery for hepatocellular carcinoma. World J Gastroenterol 2009; 15 (29) 3664-3669
36 Huang M, Wang X, Bin H. Effect of transcatheter arterial chemoembolization combined with argon-helium cryosurgery system on the changes of NK cells and T cell subsets in peripheral blood of hepatocellular carcinoma patients. Cell Biochem Biophys 2015; 73 (03) 787-792
37 Pacella CM, Bizzarri G, Francica G. , et al. Percutaneous laser ablation in the treatment of hepatocellular carcinoma with small tumors: analysis of factors affecting the achievement of tumor necrosis. J Vasc Interv Radiol 2005; 16 (11) 1447-1457
38 Ferrari FS, Megliola A, Scorzelli A. , et al. Treatment of small HCC through radiofrequency ablation and laser ablation. Comparison of techniques and long-term results. Radiol Med (Torino) 2007; 112 (03) 377-393
39 Sturesson C, Liu DL, Stenram U, Andersson-Engels S. Hepatic inflow occlusion increases the efficacy of interstitial laser-induced thermotherapy in rat. J Surg Res 1997; 71 (01) 67-72
40 Zangos S, Eichler K, Balzer JO. , et al. Large-sized hepatocellular carcinoma (HCC): a neoadjuvant treatment protocol with repetitive transarterial chemoembolization (TACE) before percutaneous MR-guided laser-induced thermotherapy (LITT). Eur Radiol 2007; 17 (02) 553-563
41 Pacella CM, Bizzarri G, Cecconi P. , et al. Hepatocellular carcinoma: long-term results of combined treatment with laser thermal ablation and transcatheter arterial chemoembolization. Radiology 2001; 219 (03) 669-678
42 Ferrari FS, Stella A, Gambacorta D. , et al. Treatment of large hepatocellular carcinoma: comparison between techniques and long term results. Radiol Med (Torino) 2004; 108 (04) 356-371
43 Zhou Y-F. High intensity focused ultrasound in clinical tumor ablation. World J Clin Oncol 2011; 2 (01) 8-27
44 Zhao LY, Liu S, Chen ZG, Zou JZ, Wu F. Cavitation enhances coagulated size during pulsed high-intensity focused ultrasound ablation in an isolated liver perfusion system. Int J Hyperthermia 2017; 33 (03) 343-353
45 Jin C, Zhu H, Wang Z. , et al. High-intensity focused ultrasound combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: long-term follow-up and clinical analysis. Eur J Radiol 2011; 80 (03) 662-669
46 Lewandowski RJ, Gabr A, Abouchaleh N. , et al. Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma. Radiology 2018; 287 (03) 1050-1058
47 Riaz A, Gates VL, Atassi B. , et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys 2011; 79 (01) 163-171
48 Salem R, Gordon AC, Mouli S. , et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2016; 151 (06) 1155-1163.e2
49 Padia SA, Johnson GE, Horton KJ. , et al. Segmental yttrium-90 radioembolization versus segmental chemoembolization for localized hepatocellular carcinoma: results of a single-center, retrospective, propensity score-matched study. J Vasc Interv Radiol 2017; 28 (06) 777-785.e1
50 Shiina S, Tagawa K, Unuma T. , et al. Percutaneous ethanol injection therapy for hepatocellular carcinoma. A histopathologic study. Cancer 1991; 68 (07) 1524-1530
51 Vilana R, Bruix J, Bru C, Ayuso C, Solé M, Rodés J. Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology 1992; 16 (02) 353-357
52 Knab LM, Salem R, Mahvi DM. Minimally invasive therapies for hepatic malignancy. Curr Probl Surg 2013; 50 (04) 146-179
53 Tanaka K, Okazaki H, Nakamura S. , et al. Hepatocellular carcinoma: treatment with a combination therapy of transcatheter arterial embolization and percutaneous ethanol injection. Radiology 1991; 179 (03) 713-717
54 Fu Y, Zhao X, Yun Q. , et al. Transarterial chemoembolization (TACE) plus percutaneous ethanol injection (PEI) for the treatment of unresectable hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Int J Clin Exp Med 2015; 8 (07) 10388-10400
55 Bujold A, Massey CA, Kim JJ. , et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 2013; 31 (13) 1631-1639
56 Demaria S, Coleman CN, Formenti SC. Radiotherapy: changing the game in immunotherapy. Trends Cancer 2016; 2 (06) 286-294
57 Murray LJ, Dawson LA. Advances in stereotactic body radiation therapy for hepatocellular carcinoma. Semin Radiat Oncol 2017; 27 (03) 247-255
58 Su TS, Lu HZ, Cheng T. , et al. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm. BMC Cancer 2016; 16 (01) 834
59 Charpentier KP, Wolf F, Noble L, Winn B, Resnick M, Dupuy DE. Irreversible electroporation of the liver and liver hilum in swine. HPB (Oxford) 2011; 13 (03) 168-173
60 Guo Y, Zhang Y, Jin N. , et al. Electroporation-mediated transcatheter arterial chemoembolization in the rabbit VX2 liver tumor model. Invest Radiol 2012; 47 (02) 116-120
61 Vollherbst D, Bertheau RC, Fritz S. , et al. Electrochemical effects after transarterial chemoembolization in combination with percutaneous irreversible electroporation: observations in an acute porcine liver model. J Vasc Interv Radiol 2016; 27 (06) 913-921.e2
62 Isfort P, Rauen P, Na HS. , et al. Does drug-eluting bead TACE enhance the local effect of IRE? Imaging and histopathological evaluation in a porcine model. Cardiovasc Intervent Radiol 2019; 42 (06) 880-885
63 Mukaida N, Nakamoto Y. Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma. World J Gastroenterol 2018; 24 (17) 1839-1858
64 Behm B, Di Fazio P, Michl P. , et al. Additive antitumour response to the rabbit VX2 hepatoma by combined radio frequency ablation and toll like receptor 9 stimulation. Gut 2016; 65 (01) 134-143
65 Niu LZ, Li JL, Zeng JY. , et al. Combination treatment with comprehensive cryoablation and immunotherapy in metastatic hepatocellular cancer. World J Gastroenterol 2013; 19 (22) 3473-3480
66 Weng DS, Zhou J, Zhou QM. , et al. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. J Immunother 2008; 31 (01) 63-71
67 Lin M, Liang S, Wang X. , et al. Cryoablation combined with allogenic natural killer cell immunotherapy improves the curative effect in patients with advanced hepatocellular cancer. Oncotarget 2017; 8 (47) 81967-81977
68 Li X, Dai D, Song X, Liu J, Zhu L, Xu W. A meta-analysis of cytokine-induced killer cells therapy in combination with minimally invasive treatment for hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2014; 38 (05) 583-591
69 Nakamoto Y, Mizukoshi E, Kitahara M. , et al. Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolization. Clin Exp Immunol 2011; 163 (02) 165-177
70 Tang C, Shen J, Feng W. , et al. Combination therapy of radiofrequency ablation and transarterial chemoembolization for unresectable hepatocellular carcinoma: a retrospective study. Medicine (Baltimore) 2016; 95 (20) e3754
71 Lin J, Jiang X, Jin X, Lu L, Bao L. Clinical outcomes of radiofrequency ablation combined with transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma: a single-center experience. Chinese J Oncol 2013; 35 (02) 144-147